SCHEDULE 13D

CUSIP Number(s):

320703408

Name of reporting person

Gavrilov Ognian Anguelov

Check the appropriate box if a member of a Group (See Instructions)

(a)

(b)

SEC use only

Source of funds (See Instructions)

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Checkbox not checked

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 20,000.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 20,000.00
10	Shared Dispositive Power 0.00

Aggregate amount beneficially owned by each reporting person

20,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in Row (11)

0.3 %

Type of Reporting Person (See Instructions)

SCHEDULE 13D

Item 1.

Security and Issuer

(a)

Title of Class of Securities:

Common Stock, $0.0001 par value

(b)

Name of Issuer:

Calidi Biotherapeutics, Inc.

(c)

Address of Issuer's Principal Executive Offices:

4475 EXECUTIVE DRIVE, SUITE 200, SAN DIEGO, CALIFORNIA , 92121.

Item 2.

Identity and Background

(a)

Ognian Anguelov Gavrilov

(b)

2315 Capitol Avenue, Sacramento, CA 95816

(c)

Managing Partner, Gavrlilov & Brooks, 2315 Capitol Avenue, Sacramento, CA 95816

(d)

No.

(e)

No.

(f)

United States of America

Item 3.

Source and Amount of Funds or Other Consideration

Not Applicable. This Schedule 13D relates to the disposition of securities by the Reporting Person.

Item 4.

Purpose of Transaction

The Reporting Person has effected dispositions of Shares as described in Item 5, resulting in beneficial ownership of approximately 0.3% of the outstanding Shares. The Reporting Person does not currently have any plans or proposals that relate to or would result in any of the actions described in Item 4 of Schedule 13D. However, the Reporting Person may, from time to time, acquire or dispose of securities of the Issuer in the open market or otherwise, depending on market conditions and other factors.

Item 5.

Interest in Securities of the Issuer

(a)

20,000.00

(b)

(c)

20,000.00

(d)

(e)

March 31, 2026

Item 6.

Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Gavrilov Ognian Anguelov

Signature:	Ognian Anguelov Gavrilov
Name/Title:	Ognian Anguelov Gavrilov, Managing Partner
Date:	03/31/2026